Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.

Détails

ID Serval
serval:BIB_E62C33C9D4C7
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.
Périodique
Blood
Auteur(s)
Haouala A., Widmer N., Duchosal M.A., Montemurro M., Buclin T., Decosterd L.A.
ISSN
1528-0020[electronic], 0006-4971[linking]
Statut éditorial
Publié
Date de publication
2011
Peer-reviewed
Oui
Volume
117
Numéro
8
Pages
e75-e87
Langue
anglais
Notes
Publication types: Journal Article Publication Status: ppublish
Résumé
Several cancer treatments are shifting from traditional, time-limited, nonspecific cytotoxic chemotherapy cycles to continuous oral treatment with specific protein-targeted therapies. In this line, imatinib mesylate, a selective tyrosine kinases inhibitor (TKI), has excellent efficacy in the treatment of chronic myeloid leukemia. It has opened the way to the development of additional TKIs against chronic myeloid leukemia, including nilotinib and dasatinib. TKIs are prescribed for prolonged periods, often in patients with comorbidities. Therefore, they are regularly co-administered along with treatments at risk of drug-drug interactions. This aspect has been partially addressed so far, calling for a comprehensive review of the published data. We review here the available evidence and pharmacologic mechanisms of interactions between imatinib, dasatinib, and nilotinib and widely prescribed co-medications, including known inhibitors or inducers of cytochromes P450 or drug transporters. Information is mostly available for imatinib mesylate, well introduced in clinical practice. Several pharmacokinetic aspects yet remain insufficiently investigated for these drugs. Regular updates will be mandatory and so is the prospective reporting of unexpected clinical observations.
Pubmed
Web of science
Open Access
Oui
Création de la notice
22/02/2011 11:33
Dernière modification de la notice
20/08/2019 16:09
Données d'usage